

해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.
- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.04.01.~2024.04.07.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 58건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06351124	Beta-Hydroxybutyrate Feasibility Treating IBS	Biological: Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Inflammatory Bowel Disease	University of Texas at Austin	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06351124
NCT06320405	Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors	Biological: Axatilimab Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Drug: Paclitaxel Procedure: Positron Emission Tomography Biological: Retifanlimab	OHSU Knight Cancer Institute Oregon Health and Science University Incyte Corporation	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06320405
NCT06249191	Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration and Biopsy Procedure: Computed Tomography Drug: Cyclophosphamide Drug: Doxorubicin Procedure: Echocardiography Drug: Etoposide Procedure: Magnetic Resonance Imaging Biological: Mosunetuzumab Procedure: Multigated Acquisition Scan Procedure: Positron Emission Tomography Drug: Prednisone Drug: Vincristine	OHSU Knight Cancer Institute Genentech, Inc. Oregon Health and Science University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06249191
NCT06238921	Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases	Radiation: Stereotactic Radiation Drug: Zimberelimab Drug: Sacituzumab govitecan	H. Lee Moffitt Cancer Center and Research Institute Gilead Sciences	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06238921
NCT06113003	The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease	Dietary Supplement: Prebiotic Dietary Supplement: Probiotic	Vanderbilt University Medical Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06113003
NCT06106672	Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis	Drug: CNP-106 Other: Placebo	COUR Pharmaceutical Development Company, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06106672
NCT06053242	Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain	Drug: CELZ-201-DDT Other: Placebo	Creative Medical Technology Holdings Inc	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06053242
NCT05669352	A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases	Drug: CA-4948 Drug: Pembrolizumab	University of Florida Merck Sharp & Dohme LLC	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05669352
NCT04085887	Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures	Drug: Panitumumab-IRDye800 Device: Pinpoint-IR9000 endoscopic/handheld device Device: Explorer Air camera Device: PDE-NEO-II	Stanford University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04085887
NCT06283459	Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2	Biological: IMNN-101	Imunon	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06283459

해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 미국 58건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06138639	A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)	Genetic: SGT-003	Solid Biosciences Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/study/NCT06138639
NCT06340711	Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma	Drug: OBP-301 Drug: Pembrolizumab	Weill Medical College of Cornell University Merck Sharp & Dohme LLC Oncolys BioPharma Inc	Phase 2	https://clinicaltrials.gov/study/NCT06340711
NCT06333652	Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders	Drug: Ravulizumab	Mayo Clinic	Phase 2	https://clinicaltrials.gov/study/NCT06333652
NCT06298019	Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis	Biological: KYV-101	Stanford University	Phase 1	https://clinicaltrials.gov/study/NCT06298019
NCT06295770	Obinutuzumab in Treatment of Fibrillary Glomerulonephritis	Drug: Obinutuzumab	Mayo Clinic	Phase 2	https://clinicaltrials.gov/study/NCT06295770
NCT06294236	Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)	Biological: SC291	Sana Biotechnology	Phase 1	https://clinicaltrials.gov/study/NCT06294236
NCT06263153	Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy	Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Durvalumab Drug: Futibatinib Procedure: Magnetic Resonance Imaging Procedure: Radical Cystectomy	Yuanquan Yang Gateway for Cancer Research Ohio State University Comprehensive Cancer Center	Phase 2	https://clinicaltrials.gov/study/NCT06263153
NCT06254326	ADAGiO: Adoptive Cellular Therapy for the Treatment of Recurrent Oligodendroglioma (OG) Adult Patients	Biological: TTRNA-DC vaccines with GM-CSF Biological: Autologous Hematopoietic Stem cells (HSCs) Biological: TTRNA-xALT Drug: Td vaccine	University of Florida Oligo Nation, Inc	Phase 1	https://clinicaltrials.gov/study/NCT06254326
NCT06245889	PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC	Drug: Paclitaxel Drug: Carboplatin Drug: Pembrolizumab Drug: Doxorubicin Drug: Cyclophosphamide Drug: Olaparib Drug: Capecitabine	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	https://clinicaltrials.gov/study/NCT06245889
NCT06124118	Tumor Treating Fields for Locally Advanced NSCLC	Radiation: carboplatin chemotherapy Device: NovoTTF-200T (TTFields) System Drug: Durvalumab	University of Utah	Phase 1	https://clinicaltrials.gov/study/NCT06124118
NCT06084780	Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)	Procedure: Intestinal, Multivisceral or Modified Multivisceral Transplantation Drug: Alemtuzumab Drug: Tacrolimus Drug: Sirolimus	Case Comprehensive Cancer Center	Phase 2	https://clinicaltrials.gov/study/NCT06084780
NCT05989828	A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer	Biological: Aldesleukin Biological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Cyclophosphamide Procedure: Echocardiography Drug: Fludarabine Procedure: Leukapheresis Procedure: Magnetic Resonance Imaging Procedure: Mammogram Procedure: Multigated Acquisition Scan Procedure: Ultrasound Imaging	University of Southern California National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/study/NCT05989828

해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 미국 58건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05854966	CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)	Drug: CPI 613 Drug: Metformin Biological: Blood draws Procedure: Bone marrow biopsy	Wake Forest University Health Sciences National Cancer Institute (NCI) Cornerstone Pharmaceuticals	Phase 2	https://clinicaltrials.gov/study/NCT05854966
NCT05833867	Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer	Drug: Sacituzumab govitecan Radiation: Adaptive Radiotherapy	Omar Mian Varian Inc Gilead Sciences Case Comprehensive Cancer Center	Phase 1	https://clinicaltrials.gov/study/NCT05833867
NCT05757310	A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia	Biological: Anti-Thymocyte Globulin Procedure: Biospecimen Collection Procedure: Bone Marrow Aspirate Procedure: Bone Marrow Biopsy Drug: Cyclophosphamide Procedure: Haploidentical Hematopoietic Cell Transplantation Drug: Pentostatin Other: Questionnaire Administration	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/study/NCT05757310
NCT05707702	Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia	Biological: Probiotic oral lozenges Other: Standard of care for oral dysplasia	Boston Medical Center University of Alabama at Birmingham	Phase 3	https://clinicaltrials.gov/study/NCT05707702
NCT05664113	Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).	Drug: Fecal microbiota transplant (FMT)	St. Jude Children's Research Hospital	Phase 1	https://clinicaltrials.gov/study/NCT05664113
NCT05632328	AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer	Drug: AGEN1423 Drug: Balstilimab Drug: Gemcitabine Drug: Nab-paclitaxel	Bruno Bockorny Agenus Inc Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center	Phase 2	https://clinicaltrials.gov/study/NCT05632328
NCT05445882	N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer	Drug: Bintrafusp alfa Drug: N-803 Biological: BN-Brachyury	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2	https://clinicaltrials.gov/study/NCT05445882
NCT05333029	Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD	Biological: Allogeneic mesenchymal stromal cells (MSCs) Biological: Extracorporeal photopheresis (ECP)	Molly Gallogly Case Comprehensive Cancer Center	Phase 2	https://clinicaltrials.gov/study/NCT05333029
NCT05264974	Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy	Biological: Autologous total tumor mRNA loaded DOTAP liposome vaccine	University of Florida	Phase 1	https://clinicaltrials.gov/study/NCT05264974
NCT05134740	(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).	Biological: TAA-specific CTLs	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1	https://clinicaltrials.gov/study/NCT05134740
NCT04579523	²¹¹ At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Cyclophosphamide Drug: Fludarabine Phosphate Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/study/NCT04579523
NCT04569461	Trimodality Approach of Low Dose iONizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)	Drug: pembrolizumab Radiation: Stereotactic body radiation therapy Drug: Short-term androgen deprivation therapy Procedure: Radical Prostatectomy	Daniel George, MD Merck Sharp & Dohme LLC Duke University	Phase 2	https://clinicaltrials.gov/study/NCT04569461
NCT06345027	CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY)	Biological: Treatment Arm A	Baylor College of Medicine	Phase 1	https://clinicaltrials.gov/study/NCT06345027

해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 미국 58건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06343402	Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer	Drug: BBO-8520 Drug: Pembrolizumab	TheRas, Inc	Phase 1	https://clinicaltrials.gov/study/NCT06343402
NCT06336902	Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer	Biological: Balstilimab Procedure: Biospecimen Collection Biological: Botensilimab Procedure: Computed Tomography Other: Dietary Intervention Procedure: Magnetic Resonance Imaging Dietary Supplement: Vitamin C	University of Southern California National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/study/NCT06336902
NCT06228924	Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC	Genetic: TN-401	Tenaya Therapeutics Johns Hopkins University Mayo Clinic	Phase 1	https://clinicaltrials.gov/study/NCT06228924
NCT06043674	A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation	Drug: Glofitamab Drug: Obinutuzumab Drug: Polatuzumab Vedotin Drug: Atezolizumab Drug: Tocilizumab	Christine Ryan Genentech, Inc. Dana-Farber Cancer Institute	Phase 2	https://clinicaltrials.gov/study/NCT06043674
NCT06006013	Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer	Biological: Atezolizumab Procedure: Biospecimen Collection Drug: Cabozantinib S-malate Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging	Emory University National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/study/NCT06006013
NCT05951777	Autologous Adipose Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury	Biological: Autologous HB-adMSCs Drug: Normal Saline	Hope Biosciences The University of Texas Health Science Center, Houston	Phase 2	https://clinicaltrials.gov/study/NCT05951777
NCT06345066	A Study of LY3841136 in Overweight and Obese Participants	Drug: Tirzepatide Drug: LY3841136 Drug: Placebo	Eli Lilly and Company	Phase 1	https://clinicaltrials.gov/study/NCT06345066
NCT06263543	Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC	Drug: Sacituzumab govitecan	Reshma L. Mahtani, D.O. Gilead Sciences Baptist Health South Florida	Phase 2	https://clinicaltrials.gov/study/NCT06263543
NCT06023277	A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer	Biological: ConvitVax	Jacinto Convit World Organization Inc. Fundación Jacinto Convit Instituto Oncologico Luis Razetti	Phase 1 Phase 2	https://clinicaltrials.gov/study/NCT06023277
NCT06227546	A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer	Drug: MGC018	Georgetown University MacroGenics	Phase 2	https://clinicaltrials.gov/study/NCT06227546
NCT05937152	A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy	Drug: Eptinezumab Drug: Placebo	Mayo Clinic	Phase 2	https://clinicaltrials.gov/study/NCT05937152
NCT06249048	Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab	Biological: STX-001 Biological: Keytruda	Strand Therapeutics Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/study/NCT06249048
NCT05952804	IVIG for Infection Prevention After CAR-T-Cell Therapy	Biological: Immune Globulin Infusion (Human), 10% Solution Biological: Anti-CD19 CAR T Cells Preparation Other: Saline Procedure: Biospecimen Collection Other: Survey Administration Other: Electronic Health Record Review	Fred Hutchinson Cancer Center Takeda National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/study/NCT05952804

해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 미국 58건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05835206	Further MT for Antibiotic-Resistant Bacterial Colonization in Inpatients	Drug: Microbiome Therapeutic Drug: Placebo	Emory University Centers for Disease Control and Prevention	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05835206
NCT05985681	Testing RG1-VLP Vaccine to Prevent HPV-related Cancers	Procedure: Biospecimen Collection Biological: HPV16 RG1 VLP Vaccine Other: Questionnaire Administration Biological: Recombinant Human Papillomavirus Nonavalent Vaccine Other: Saline	National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05985681
NCT06071767	Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1	Biological: ChAdOx1.tHIVconsV1 Biological: ChAdOx1.HIVconsV62 Biological: MVA.tHIVconsV3 Biological: MVA.tHIVconsV4 Drug: Vesatolimod (VES) Drug: GS-5423 Drug: GS-2872 Biological: Placebo	National Institute of Allergy and Infectious Diseases (NIAID) University of Oxford Gilead Sciences	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06071767
NCT05703971	Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients	Biological: quaratusugene ozeplasmid Biological: atezolizumab	Genprex, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05703971
NCT06200207	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation	Drug: Ziltivekimab Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06200207
NCT06195072	Platform Clinical Study for Conquering Scleroderma	Drug: Amltelimab Drug: BI 1015550 Drug: Placebo	Scleroderma Research Foundation, Inc. Sanofi Boehringer Ingelheim	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06195072
NCT06131372	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06131372
NCT06014762	P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies	Biological: P-CD19CD20-ALLO1 Drug: Rimiducid	Poseida Therapeutics, Inc. Roche-Genentech	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06014762
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT06163391	A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer	Drug: SOT201	SOTIO Biotech AG Sotio Biotech Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06163391

○ 영국 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06320535	A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™	Biological: R21/Matrix M™(Group 1) Biological: R21/Matrix M™(Group 2) Biological: R21/Matrix M™(Group 3) Procedure: Fine needle aspiration (FNA)	University of Oxford Bill and Melinda Gates Foundation University Hospitals Bristol and Weston NHS Foundation Trust	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06320535
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT06200207	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation	Drug: Ziltivekimab Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06200207
NCT05718297	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05718297

해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 프랑스 9건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06037460	Tocilizumab discontinuation in Giant Cell Arteritis	Drug: Tocilizumab treatment Other: questionnaires Biological: Blood samples Procedure: 18FDG PET scan	Centre Hospitalier Universitaire Dijon	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06037460
NCT06276504	Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection	Drug: Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection	Assistance Publique - Hôpital de Paris	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06276504
NCT06306014	Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients	Drug: EXL01 Drug: Placebo	Hospices Civils de Lyon Exelium Biosciences	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06306014
NCT06284122	Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5	Drug: Mosunetuzumab Drug: Lenalidomide Drug: Rituximab Drug: Obinutuzumab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristin Drug: Prednisone Drug: Bendamustine	The Lymphoma Academic Research Organisation Lymphoma Study Association Swiss Group for Clinical Cancer Research Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06284122
NCT06131372	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06131372
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT06200207	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation	Drug: Ziltivekimab Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06200207
NCT05718297	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05718297
NCT06163391	A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer	Drug: SOT201	SOTIO Biotech AG Sotio Biotech Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06163391

○ 독일 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06243393	Sacituzumab Govitecan in Metastatic Colorectal Cancer	Drug: Sacituzumab Govitecan (SG) Drug: Physicians Choice (PhC).	University Hospital Heidelberg	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06243393
NCT06200207	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation	Drug: Ziltivekimab Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06200207
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598

해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 독일 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06163573	Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.	Biological: N-TEC Biological: Platelet rich plasma	University Hospital, Basel, Switzerland Swiss National Science Foundation Clinical Trial Unit, University Hospital Basel, Switzerland Wuerzburg University Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06163573
NCT06284122	Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5	Drug: Mosunetuzumab Drug: Lenalidomide Drug: Rituximab Drug: Obinutuzumab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristin Drug: Prednisone Drug: Bendamustin	The Lymphoma Academic Research Organisation Lymphoma Study Association Swiss Group for Clinical Cancer Research Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06284122

○ 중국 23건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06345482	A Study of MHB039A for Advanced Solid Tumor	Drug: MHB039A	Minghui Pharmaceutical (Hangzhou) Ltd	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06345482
NCT06332950	Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy	Drug: Adebrelimab, Irinotecan Liposome (II) Drug: Adebrelimab, Irinotecan Liposome (II), Famitinib	Baohui Han Shanghai Chest Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06332950
NCT06283719	Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer	Biological: ZG006	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06283719
NCT05745740	A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation	Drug: RC48-ADC Drug: Pyrotinib	RemeGen Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05745740
NCT06344156	Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer	Drug: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy	Sichuan University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06344156
NCT06343948	A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer	Drug: BL-B01D1 Drug: Eribulin Drug: Vinorelbine Drug: Gemcitabine Drug: Capecitabine	Sichuan Baili Pharmaceutical Co., Ltd. Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06343948
NCT06341595	Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM	Drug: Sintilimab Radiation: Extraperitoneal radiation therapy Drug: Oxaliplatin Drug: S-1	The First Affiliated Hospital with Nanjing Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06341595
NCT06331169	Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer	Drug: Anlotinib Drug: Trastuzumab deruxtecan	Fudan University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06331169
NCT06331026	A Bioequivalence Study of Two Different PEG-rhGH Preparations.	Drug: PEG-rhGH with new preparation (T) Drug: PEG-rhGH with present preparation (R)	Changchun GeneScience Pharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06331026

해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 중국 23건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06322563	Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC	Drug: LTC004+regorafenib	Tianjin Medical University Cancer Institute and Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06322563
NCT06320301	Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)	Drug: Adebrelimab + GEMOX + TKI	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06320301
NCT06316531	A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer	Drug: BL-M07D1 Drug: T-DM1	Sichuan Baili Pharmaceutical Co., Ltd. Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06316531
NCT06313190	Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)	Radiation: Stereotactic body radiotherapy Drug: Sintilimab	Sun Yat-sen University Fifth Affiliated Hospital, Sun Yat-Sen University Ningbo Medical Center Lihuli Eastern Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06313190
NCT06202716	Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEScore	Drug: Cadonilimab plus CapeOX chemotherapy	Nanfang Hospital, Southern Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06202716
NCT06319456	A Global Study of Lisoftoclax (APG-2575) Combined With Acalabrutinib Versus Immunotherapy for Newly Diagnosed CLL/SLL.	Drug: Lisoftoclax (APG-2575) Drug: Acalabrutinib Drug: Fludarabine Drug: Cyclophosphamide, CTX Drug: Rituximab Drug: Chlorambucil	Ascentage Pharma Group Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06319456
NCT06301386	Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients	Drug: Everolimus Drug: PD-1	Fudan University Anyang Tumor Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06301386
NCT06206902	F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma	Drug: After preconditioning with chemotherapy, F01 will be evaluated.	Shanghai Simnova Biotechnology Co.,Ltd. Wuhan Union Hospital, China	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06206902
NCT06320080	Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.	Drug: TQB2223 injection Drug: Penpulimab Injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06320080
NCT06318884	A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma	Drug: SCTB35 injection	Sinocelltech Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06318884
NCT06297642	TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.	Drug: TQB2928 injection Drug: Penpulimab	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06297642
NCT05850546	Rituximab in the First Episode of Paediatric Nephrotic Syndrome	Drug: Rituximab Drug: Corticosteroid	Children's Hospital of Fudan University Shanghai Shen Kang Hospital Development Center Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Children's Medical Center Shanghai Children's Hospital	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05850546

해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 중국 23건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06205862	Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Reducing Recurrence of Colorectal Adenoma (CRA)	Procedure: fecal microbiota transplantation	Shenzhen Hospital of Southern Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06205862
NCT06297655	A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A	Drug: Recombinant human activated coagulation factor VIII for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.[Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06297655

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06297616	A Study of LY3841136 in Japanese Participants With Obesity or Overweight	Drug: LY3841136 Drug: Placebo	Eli Lilly and Company	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06297616
NCT06131372	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06131372